Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


CMS Updates Drug Dashboards with Prescription Drug Pricing and Spending Data


 

Today, the Centers for Medicare & Medicaid Services (CMS) updated its Drug Spending Dashboards with data for 2017. This Administration's version of the drug dashboards, first released in May of last year, adds information on the manufacturers that are responsible for price increases and includes pricing and spending data for thousands more drugs across Medicare Parts B and D and Medicaid.

The dashboards focus on average spending per dosage unit for prescription drugs paid under Medicare Parts B and D and Medicaid, and track the change in average spending per dosage unit over time. Information is presented in an interactive web-based tool, so researchers and consumers can easily sort the data to identify trends.

Drugs with limited to no competition can be identified using the dashboard, by sorting for drugs with few manufacturers. Information is also provided on drug uses and clinical indications, so patients and physicians can compare the list prices of different medications for a given condition.

"Today's update to the drug dashboards continues the Trump Administration's commitment to price transparency. The dashboards pinpoint the sources of rising prescription drug prices to help guide our continued work to address this problem," said CMS Administrator Seema Verma. "From 2013-2017, prescription drug spending grew at an average annual rate of 10.6 percent in Medicare Part D, 10.0 percent in Part B, and 14.8 percent in Medicaid - this is one of our fastest areas of growth."

The dashboards complement other CMS efforts to increase transparency on drug prices, including recent proposals to require prescription drug manufacturers to include list prices in television advertisements and proposals to implement legislation signed by President Trump to end the practice of pharmacy gag clauses. Pharmacy gag clauses can prevent pharmacists from telling patients how to access prescription drugs at the lowest cost.

In 2017, total gross spending on prescription drugs was $154.9 billion in Medicare Part D, $30.4 billion in Part B, and $67.6 billion in Medicaid.

The CMS Drug Spending Dashboards can be accessed at: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Information-on-Prescription-Drugs/index.html

 
Share:

Related Articles:


Recent Articles

Study Finds Certain Genetic Test Not Useful in Predicting Heart Disease Risk

A Polygenic Risk Score -- a genetic assessment that doctors have hoped could predict coronary heart disease (CHD) in patients -- has been found not to be a useful predictive biomarker for disease risk, according to a Vanderbilt study published in the Journal of the American Medical Association.

Read More

Tennessee Infants Exposed to Hep C at Birth Often Not Tested for Virus

Most Tennessee infants exposed to hepatitis C at birth are not later tested to see if they acquired the virus, according to a study by researchers at Monroe Carell Jr. Children's Hospital at Vanderbilt and the Vanderbilt Center for Child Health Policy.

Read More

THA, TMA, TNA Outline Legislative Priorities

With the Tennessee General Assembly back in full swing, the state's major healthcare associations outline 2020 priorities.

Read More

Cardiac Innovation in Nashville

From transplants to trials, Nashville hospitals are leading the way in cardiac care.

Read More

A Modern Love Story: Where Technology, Healthcare & Construction Go Hand-in-Hand

Technology has changed every aspect of our lives. In fact, I had a healthy laugh a few weeks ago when I showed my children an old rotary phone and, get this, they did not know what it was.

Read More

Reeves/Smith Bill to Prevent Next Generation of Nicotine Addiction Garners Broad Industry Support

In late January, a group of more than 25 organizations from across Tennessee announced their support for legislation that seeks to prevent the next generation of nicotine addicts in the state.

Read More

Physician Spotlight: A Heart for Healing

TriStar Summit cardiologist Kristen Kerr is passionate about education, improving outcomes in women's heart health.

Read More

Heart Monitor

Read More

Ifetroban for Treating DMD-Associated Cardiomyopathy

Following successful preclinical trials and FDA funding, Cumberland Pharmaceuticals is preparing to launch a new Phase II trial of ifetroban to treat cardiomyopathy in Duchenne Muscular Dystrophy patients.

Read More

Endocrine Society Celebrates Progress from Bench to Bedside

Endocrine Society Chief Professional & Clinical Affairs Officer Robert Lash, MD, discusses the field, annual meeting, road shows and more.

Read More

Email Print
 
 

 

 


Tags:
None
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: